Author: Kyosuke Baba

The Life Biomedical Science Advisors and Sub-Advisors will be involved in the development and research of new fields related to our future-oriented advanced technologies. We are delighted to welcome TEMIZOZ Burcu, a promising researcher and Assistant Professor at the Institute of Medical Science, The University of Tokyo, to join us as a Life Science Sub-Advisor. …

Read more “We are pleased to announce that two researchers have been preliminarily selected for the positions of Life Biomedical Science Advisor and Sub-Advisor as previously mentioned in our press release.”

After years of foundational research, our company made a presentation at the Japanese Society of Laboratory Medicine’s national conference on August 29, 2025. By the end of September 2025, we commenced the release of FLD HbA1c through our app store, ‘SFM App Store.’ Since the launch of the SFM App Store, the number of access …

Read more “SFM App Store Access: Over 150,000 Access Requests in 40 Days”

A portion of our innovative technology was presented at the nationwide conference of the Japanese Society of Laboratory Medicine in August 2025. Furthermore, in September 2025, we commenced the release of the Android-based application “FLD HbA1c.” Additionally, on October 22, 2025, we began releasing the “FLD HbA1c” app in seven countries across Southeast and Southwest …

Read more “Regarding the Appointment of Life Medical Science Advisors and Sub – Advisors”

We are pleased to announce the expansion of release countries within Asia and Central America. The countries included are as follows: The app can be installed from the SFM App Store. SFM App Store We plan to continue increasing the number of release countries, and will provide updates via press releases as more countries are …

Read more “We have expanded the foreign target countries for FLD HbA1c.[the third phase]”

After years of foundational research, our company made a presentation at the national conference of the Japanese Society of Laboratory Medicine on August 29, 2025. By the end of September 2025, we began releasing FLD HbA1c through our app store, the “SFM App Store.” Since its launch, the SFM App Store has exceeded 110,000 access …

Read more “SFM App Store access count (number of access requests) exceeds 110,000 in one month.”

After years of fundamental research, we have released our proprietary development, “FLD HbA1c,” in September 2025. We are pleased to announce the completion of the Android tablet version. The tablet version is designed with large-scale facilities and corporations in mind for its utilization. （The iPad version is scheduled for release in January 2026.）

SFM will advance its expansion into the global market starting October 22, 2025, coinciding with the release of FLD HbA1c for Android in Southeast and Southwest Asia. In preparation for our future global expansion, we have commenced the development of an English version of our company website. Leveraging our cutting-edge, future-focused technology, we are committed …

Read more “Regarding the development of the English version of our website”

The Future Laboratory Data® (FLD) system by our company has been installed and is now operational in the new headquarters of the Institute for Quantitative Biosciences (IQB) at the University of Tokyo. FLD is an unprecedented non-contact, non-invasive biomarker measurement device capable of simultaneously measuring Hemoglobin A1c (HbA1c), oxygen saturation, and pulse in a short …

Read more “Operation of FLD® Begins at the New Main Building of the Quantitative Life Sciences Institute, University of Tokyo”

We commenced the domestic release of FLD HbA1c for Android via the SFM App Store in last September 2025. We are pleased to announce that, as the first phase of out overseas expansion, we have decided to release FLD HbA1c for Android in seven countries across Southeast and Southwest Asia. The subscription fee will be …

Read more “Regarding the Launch of Overseas Sales for FLD HbA1c for Android”

It has been decided that our Future Laboratory Data® (FLD) system will be implemented at the main building of the Institute for Quantitative Biosciences (IQB) at the University of Tokyo, with installation scheduled for completion within this month. The FLD is a non-contact, non-invasive biomarker measurement device that is unparalleled globally, capable of simultaneously measuring …

Read more “FLD to be Installed at the Institute of Quantitative Biosciences Main Building, the University of Tokyo”